562791-56-4
Chemical Structure
ErbB-2-binding peptide-1
Synonym(s): LTVSPWY
- CAS. Nr.: 562791-56-4
- Formula:C43H60N8O11
- Molecular Weight:864.98
IUPAC Name: oleoyl-D-lysine
InChIKey: PGERLHWWNPYTKW-NQDQSAFWSA-N
SMILES: O=C(N[C@@H]([C@H](O)C)C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N1[C@@H](CCC1)C(N[C@@H](CC2=CNC3=CC=CC=C23)C(N[C@@H](CC4=CC=C(C=C4)O)C(O)=O)=O)=O)=O)=O)=O)[C@H](CC(C)C)N
Biological Activity: ErbB-2-binding peptide-1 (LTVSPWY) is a HER2 receptor-binding peptide. ErbB-2-binding peptide-1 can be conjugated with nuclear cross-linked micelles loaded with Doxorubicin (HY-15142A). ErbB-2-binding peptide-1 can also be radiolabeled to form 177Lu-DOTA-LTVSPWY. ErbB-2-binding peptide-1 is conjugated with antisense oligonucleotides. ErbB-2-binding peptide-1 can be used in research related to HER2-positive breast cancer and ovarian cancer[1][2][3].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ErbB-2-binding peptide-1 | 99.52% | ErbB-2-binding peptide-1 (LTVSPWY) is a HER2 receptor-binding peptide. ErbB-2-binding peptide-1 can be conjugated with nuclear cross-linked micelles loaded with Doxorubicin (HY-15142A). ErbB-2-binding peptide-1 can also be radiolabeled to form 177Lu-DOTA-LTVSPWY. ErbB-2-binding peptide-1 is conjugated with antisense oligonucleotides. ErbB-2-binding peptide-1 can be used in research related to HER2-positive breast cancer and ovarian cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Bayram NN, et al. HER2-Specific Peptide (LTVSPWY) and Antibody (Herceptin) Targeted Core Cross-Linked Micelles for Breast Cancer: A Comparative Study. Pharmaceutics. 2023 Feb 22;15(3):733. [Content Brief]
- [2]. Shadidi M, et al. Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. FASEB J. 2003 Feb;17(2):256-8. [Content Brief]
- [3]. Molavipordanjani S, et al. The preclinical study of 177Lu-DOTA-LTVSPWY as a potential therapeutic agent against HER2 overexpressed cancer. Ann Nucl Med. 2023 Jul;37(7):400-409. [Content Brief]
Keywords
